What is the ASPN stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Aspen Aerogels, Inc. have a median 12-month price target of $7.75, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ASPN stock a buy right now?
Of the 6 analysts covering Aspen Aerogels, Inc., 4 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Aspen Aerogels, Inc. 62 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ASPN?
As at 12 Sept 2026, Aspen Aerogels, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).
Will ASPN stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +57.8% from the last close, and Ticker Nerd's factor model ranks Aspen Aerogels, Inc. 62 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ASPN stock forecast for 2030?
No analyst covering Aspen Aerogels, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.
How has ASPN stock performed over the past year?
Aspen Aerogels, Inc. returned -27.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aspen Aerogels, Inc. do?
Aspen Aerogels, Inc. is an aerogel technology company that designs, develops, manufactures, and sells advanced insulation materials for industrial, energy, and electric vehicle applications.
What is the latest news on ASPN?
The most recent item we track (Seeking Alpha, 10 Aug 2026): "Aspen Aerogels: Green Shoots Fail To Truly Impress Investors". Aspen Aerogels posted sequential revenue and EBITDA gains, with Q2 revenue exceeding guidance and Q3 outlook indicating further recovery, although shares failed to truly impress investors. Thermal Barrier sales rebounded sequentially, especially in Europe, but remain pressured by regulatory shifts and evolving battery technologies, while its EBITDA break-even threshold was lowered to $175 million in annual revenue.